Benten Technologies

What Benten Technologies does

Benten Technologies is a privately held, for-profit company founded in 2001 and headquartered in Manassas, Virginia, with 11-50 employees. The company focuses on building a pipeline of digital therapeutic products aimed at addressing health disparities, positioning it within the digital health and health equity technology sectors.

The company's operations appear to be primarily research and development driven, with cumulative disclosed funding of approximately $6.01M sourced almost entirely from National Institutes of Health grants across four rounds from 2019 to 2021, supplemented by participation in the MassChallenge accelerator in 2023. No product launches, customer relationships, pricing models, or revenue mechanics are disclosed. The company's website presents only a verification/waiting page, providing no substantive product or commercial information.

Benten Technologies has a single disclosed leader — CEO Tony Ma — and no publicly available details on its management team, board composition, product architecture, technology stack, or go-to-market strategy. The company appears to be at a pre-commercial or very early stage, with its strategic posture centered on non-dilutive grant funding for R&D rather than commercial revenue generation. This profile suggests an early-stage entity whose primary challenge is transitioning from grant-funded research to commercial product delivery.

Name

Benten Technologies

Website

https://bententech.com

Company type

Private

Founded year

2001

Headcount range

11–50 employees

Short description

Benten Technologies is a privately held digital therapeutics company founded in 2001, based in Manassas, Virginia, developing a pipeline of products to address health disparities, primarily funded through NIH grants.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Software Publishers (5132), Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Prescription Digital Therapeutics (PDT) (HLACANAB)

akta.pro secondary industry

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Digital therapeutics
• Health disparity solutions
• Therapeutic software
• Health equity technology
• Behavioral health software

Headquarters

HQ city

Manassas

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Benten Technologies develops a pipeline of digital therapeutic products aimed at addressing health disparities. The company builds software-based interventions designed to improve health outcomes in underserved populations. Its product development has been primarily funded through U.S. federal grants from the National Institutes of Health and accelerator support from MassChallenge.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights2 records

Direct peers

• Pear Therapeutics: Historically prominent prescription digital therapeutics company that developed FDA-authorized PDT products before winding down operations. Relevant comparable as a PDT-focused small DTx developer illustrating execution and capital challenges in the space.
• Akili Interactive: Pioneering prescription digital therapeutic company (now operating as Virtual Therapeutics) developing FDA-cleared software-based treatments for cognitive disorders. Direct comparable as a small, science-led DTx developer targeting specific patient populations.
• Cognoa: Pediatric digital therapeutics and diagnostics company with FDA-authorized autism diagnostic SaMD. Comparable as a focused DTx/SaMD developer targeting underserved pediatric populations with regulatory validation.
• Mahana Therapeutics: Digital therapeutics company developing prescription digital therapeutics for gastrointestinal and other chronic conditions. Comparable as a small-cap DTx developer building a condition-specific product pipeline.
• Omada Health: Digital therapeutic platform for chronic disease prevention and management (diabetes, hypertension, musculoskeletal). Comparable as a payer-reimbursed DTx company with an evidence-led approach to underserved populations.
• WellDoc: Digital health company developing FDA-cleared software for chronic disease management, particularly diabetes. Comparable as an early-stage evidence-driven DTx developer pursuing regulated SaMD pathways.
• Big Health: Digital therapeutics company developing evidence-based behavioral medicine apps for insomnia and anxiety. Comparable as a focused, evidence-driven DTx company with product pipelines targeting specific conditions.

Broad incumbents

• Verily Life Sciences: Alphabet-backed precision health technology company with significant digital health, evidence generation, and health-equity programs. Relevant as a large incumbent active across the broader DTx, real-world evidence, and health-disparities spaces.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/bententech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Benten Technologies